<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ambrisentan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ambrisentan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ambrisentan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11710" href="/d/html/11710.html" rel="external">see "Ambrisentan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708620"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Embryo-fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Do not administer ambrisentan to a pregnant female because it may cause fetal harm. Ambrisentan is very likely to produce serious birth defects if used by pregnant females as this effect has been seen consistently when it is administered to animals.</p>
<p style="text-indent:-2em;margin-left:2em;">Exclude pregnancy before the initiation of treatment with ambrisentan. Females of reproductive potential must use acceptable methods of contraception during treatment with ambrisentan and for 1 month after treatment. Obtain monthly pregnancy tests during treatment and 1 month after discontinuation of treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the risk of embryo-fetal toxicity, for all female patients, ambrisentan is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Ambrisentan REMS program.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57397487"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Letairis</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397488"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Ambrisentan;</li>
<li>JAMP-Ambrisentan;</li>
<li>SANDOZ Ambrisentan;</li>
<li>Volibris</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F5032857"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Endothelin Receptor Antagonist;</li>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F5032893"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult a pulmonary arterial hypertension specialist for all management decisions; choice of therapy is dependent on etiology, risk stratification, and cardiopulmonary comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 mg once daily; may increase to 10 mg once daily after ~4 weeks as tolerated.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990857"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild-to-moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988079"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting impairment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment: There are no dosage adjustments provided in the manufacturer’s labeling; exposure may be increased.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate or severe impairment: Use not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution and monitor closely.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:6em;">ALT or AST &gt;3 times ULN at baseline: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Impairment developing during therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">ALT or AST  &gt;5 times ULN: Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">ALT or AST increased with signs/symptoms of hepatic injury or with bilirubin &gt;2 times ULN: Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">ALT or AST &gt;3 times ULN: Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">ALT or AST increased with signs/symptoms of hepatic injury or with bilirubin &gt;2 times ULN: Discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">May consider reinitiation after ALT or AST levels normalize and if there are no signs/symptoms of hepatic injury or jaundice.</p></div>
<div class="block doe drugH1Div" id="F5032894"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F5032869"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Peripheral edema (14% to 38%), flushing (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Headache (34%)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Dyspepsia (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Oligospermia</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Decreased hemoglobin (7% to 10%; dose-dependent), anemia (7%), decreased hematocrit</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Nasal congestion (6% to 16%), cough (13%), bronchitis (4%), sinusitis (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Cardiac failure, dizziness, fatigue, fluid retention, hypersensitivity, hypotension, increased liver enzymes, nausea, vomiting, weakness</p></div>
<div class="block coi drugH1Div" id="F5032865"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Pregnancy; idiopathic pulmonary fibrosis, including idiopathic pulmonary fibrosis with pulmonary hypertension (WHO Group 3)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to ambrisentan or any component of the formulation; severe hepatic impairment (with or without cirrhosis); ALT or AST &gt;3 times ULN at baseline; breastfeeding</p></div>
<div class="block war drugH1Div" id="F5032866"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid retention/peripheral edema: Development of peripheral edema due to treatment and/or disease state (pulmonary arterial hypertension) may occur; a higher incidence is seen with concomitant use of tadalafil and in elderly patients. There have also been postmarketing reports of fluid retention requiring treatment (eg, diuretics, fluid management, hospitalization). Further evaluation may be necessary to determine cause and appropriate treatment or discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic changes: A reduction in hematocrit/hemoglobin may be observed within the first few weeks of therapy with subsequent stabilization of levels. Hemoglobin reductions &gt;15% have been observed in some patients. Measure hemoglobin prior to initiating therapy, at 1 month, and periodically thereafter. Significant decreases in hemoglobin in the absence of other causes may warrant the discontinuation of therapy. Use not recommended in patients with clinically significant anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Increases in serum liver aminotransferases have been reported during postmarketing use; however, in the majority of the cases, alternative causes of hepatotoxicity could be identified. Perform liver enzyme testing when clinically indicated. Discontinue therapy if signs/symptoms of hepatic injury appear, if serum liver aminotransferases &gt;5 times ULN (US labeling) or &gt;3 times ULN (Canadian labeling) are observed, or if aminotransferases are increased in the presence of bilirubin &gt;2 times ULN. Hepatotoxicity has been reported with other endothelin receptor antagonists (eg, bosentan); however, ambrisentan may be tried in patients that have experienced asymptomatic increases in liver enzymes caused by another endothelin receptor antagonist after the liver enzymes have returned to normal.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution in patients with mild hepatic impairment; ambrisentan exposure may be increased. The US labeling does not recommend use in patients with moderate or severe impairment. The Canadian labeling recommends use with caution in moderate impairment with monthly monitoring of ALT/AST during therapy and contraindicates use in severe hepatic impairment (with or without cirrhosis) and in patients with ALT or AST &gt;3 times ULN at baseline.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary veno-occlusive disease (PVOD): Discontinue in any patient with pulmonary edema suggestive of PVOD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pregnancy:<b> [US Boxed Warning]: </b>
<b>Do not administer ambrisentan to a pregnant female because it may cause fetal harm. Ambrisentan is very likely to produce serious birth defects if used by pregnant females as this effect has been seen consistently when it is administered to animals. Exclude pregnancy before the initiation of treatment with ambrisentan. Females of reproductive potential must use acceptable methods of contraception during treatment with ambrisentan and for 1 month after treatment. Obtain monthly pregnancy tests during treatment and 1 month after discontinuation of treatment.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program: <b>[US Boxed Warning]: Because of the risk of embryo-fetal toxicity, for all female patients, ambrisentan is only available through a restricted program under a REMS called the Ambrisentan REMS program.</b> Female patients (regardless of reproductive potential), prescribers, and pharmacies that dispense ambrisentan must be registered with and meet conditions of the program. Call 1-888-417-3172 or visit https://www.ambrisentanrems.us.com for more information.</p></div>
<div class="block foc drugH1Div" id="F5032903"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Letairis: 5 mg, 10 mg [contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F5032855"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324139"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ambrisentan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $242.67 - $368.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $242.67 - $368.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Letairis Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $519.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $519.22</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57397489"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Volibris: 5 mg, 10 mg [contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F5032899"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Swallow tablet whole. Do not split, crush, or chew tablets. Administer with or without food. </p></div>
<div class="block hazard drugH1Div" id="F49104428"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block meg drugH1Div" id="F7885303"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F022081s041lbl.pdf%23page%3D26&amp;token=P1HZGwNROzSygfF%2BYME8XWEobuw7rXQNvPHJseAgch4UuQF9xQLUtk%2B3Ci6WbaTsVBC6IkWxTe1TBb8TM9hFPqxL2n9z%2FiYLm3Pj%2BoUhG6%2BPwo41K5U8dHl5Rer6Ay3%2B&amp;TOPIC_ID=8653" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022081s041lbl.pdf#page=26</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F5032860"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">
<b>Pulmonary arterial hypertension: </b>Treatment of pulmonary artery hypertension (PAH) (World Health Organization [WHO] Group I) to improve exercise ability and delay clinical worsening; in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Studies establishing effectiveness included predominantly patients with WHO Functional Class II to III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).</p></div>
<div class="block mst drugH1Div" id="F22120172"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Ambrisentan may be confused with Ambien</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Letaris, a formerly marketed Dutch brand name product for letrozole, may be confused with Letairis, a US brand name for ambrisentan.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F5032876"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP3A4 (minor), OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor), UGT1A3, UGT1A9, UGT2B7; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F5032875"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of Ambrisentan. Management: Limit ambrisentan dose to 5 mg daily and monitor for ambrisentan adverse reactions in patients receiving cyclosporine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May enhance the adverse/toxic effect of Endothelin Receptor Antagonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095556"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: </b>
<b>Exclude pregnancy before the initiation of treatment with ambrisentan. </b>Females of reproductive potential must have a negative pregnancy test prior to initiation of therapy.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>[US Boxed Warning]: Females of reproductive potential must use acceptable methods of contraception during treatment and for 1 month after treatment. Obtain monthly pregnancy tests during treatment and 1 month after discontinuation of treatment. </b>One highly effective form of contraception (intrauterine device, contraceptive implant, or tubal sterilization) or a combination of contraceptive methods (hormone contraceptive with a barrier method or 2 barrier methods) may be used. If the partner has had a vasectomy, a hormone or barrier method must also be used. A missed menses or suspected pregnancy should be reported to a health care provider and prompt immediate pregnancy testing.</p>
<p style="text-indent:0em;margin-top:2em;">Sperm counts may be reduced in men during treatment (as observed with bosentan).</p></div>
<div class="block pri drugH1Div" id="F5032862"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ambrisentan is contraindicated in pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>[US Boxed Warning]: </b>
<b>Do not administer ambrisentan to a pregnant female because it may cause fetal harm. Ambrisentan is very likely to produce serious birth defects if used by pregnant females because this effect has been seen consistently when it is administered to animals. </b></p>
<p style="text-indent:0em;margin-top:2em;">Females with pulmonary arterial hypertension are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).</p></div>
<div class="block brc drugH1Div" id="F20520923"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ambrisentan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F5032901"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for significant peripheral edema and evaluate etiology if it occurs; hepatic enzyme testing when clinically appropriate. The Canadian labeling recommends hepatic function testing at baseline then as clinically indicated (all patients) and monthly during therapy (patients with moderate impairment or other risk factors [eg, significant right heart failure, preexisting hepatic disease or previously elevated transaminases, concurrent medications known to increase transaminases]).</p>
<p style="text-indent:0em;margin-top:2em;">Females of childbearing potential must have a negative pregnancy test prior to the initiation of therapy, monthly during treatment, and 1 month after stopping treatment. Hemoglobin and hematocrit should be measured at baseline, at 1 month, and periodically thereafter (generally stabilizes after the first few weeks of treatment).</p></div>
<div class="block pha drugH1Div" id="F5032882"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks endothelin receptor subtypes ET<sub>A</sub> and ET<sub>B</sub> on vascular endothelium and smooth muscle. Stimulation of ET<sub>A</sub> receptors, located primarily in pulmonary vascular smooth muscle cells is associated with vasoconstriction and cellular proliferation. Stimulation of ET<sub>B</sub> receptors, located in both pulmonary vascular endothelial cells and smooth muscle cells is associated with vasodilation,  antiproliferative effects, and endothelin clearance. Although ambrisentan blocks both ET<sub>A</sub> and ET<sub>B</sub> receptors, the affinity is greater for the ET<sub>A</sub> receptor (&gt;4,000-fold higher affinity).</p></div>
<div class="block phk drugH1Div" id="F5032884"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4, CYP2C19, and uridine 5'-diphosphate glucuronosyltransferases (UGTs) 1A9S, 2B7S, and 1A3S; <i>in vitro</i> studies also suggest it is a substrate of organic anion transporting polypeptides (OATP) 1B1 and 1B3 and P-glycoprotein (P-gp) </p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~9 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: ~2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily nonrenal</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6875347"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Briotaz | Brysentis | Volibris</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan aop | Ambrisentan ratiopharm | Volibris</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan mylan | Cipla ambrisentan | Volibris</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ambrisan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan sandoz | Volibris</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan teva | Ambrisentan zentiva | Volibris</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan devatis | Ambrisentan mepha | Volibris</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Beverix | Endobloc | Volibris</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan zentiva | Volibris</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ambrisen 1A pharma | Ambrisentan abz | Ambrisentan accord | Ambrisentan al | Ambrisentan aop | Ambrisentan beta | Ambrisentan bluefish | Ambrisentan cipla | Ambrisentan devatis | Ambrisentan heumann | Ambrisentan mylan | Ambrisentan ratiopharm | Ambrisentan zentiva | Volibris</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan mylan | Volibris</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Gardovas</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan cipla | Ambrisentan dr. reddys | Ambrisentan kern pharma | Ambrisentan sala | Ambrisentan sandoz | Volibris</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Volibris</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan eg | Ambrisentan mylan | Ambrisentan ohre pharma | Ambrisentan reddy | Ambrisentan teva | Volibris</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan mylan | Volibris</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan azr | Volibris</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Volibris</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ambrican | Endobloc | Ibitan | Pulmonext | Volibris</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan medac | Ambrisentan mylan | Ambrisentan reddy | Ambrisentan zentiva | Volibris</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan kmp | Ambrisentan sawai | Volibris</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan aop | Ambrisentan mylan | Ambrisentan norameda | Ambrisentan teva | Ambrisentan zentiva | Volibris</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan mylan | Ambrisentan norameda | Ambrisentan zentiva | Volibris</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Volebris</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan CF | Ambrisentan mylan | Ambrisentan sandoz | Ambrisentan teva | Volibris</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan mylan | Ambrisentan teva | Volibris</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan mylan | Ambrisentan viatris | Volibris</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Brisen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Letairis</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentano Accord | Volibris</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Ambrisentan bluefish | Ambrisentan mylan | Ambrisentan sandoz | Volibris</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan aop | Ambrisentan zentiva | Volibris</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ampaho | Volibris | Volimra</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Volibris</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ambrisentan accord | Volibris</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Volibris | Volmaro</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. <i>Eur Heart J.</i> 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. <i>Chest</i>. 2019;155(3):565–586. doi:10.1016/j.chest.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17338931">
<a name="17338931"></a>Langleben D, “Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension,” <i>Clin Chest Med</i>, 2007, 28(1):117-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/17338931/pubmed" id="17338931" target="_blank">17338931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Letairis.1">
<a name="Letairis.1"></a>Letairis (ambrisentan) [prescribing information]. Foster City, CA: Gilead; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19389575">
<a name="19389575"></a>McLaughlin VV, Archer SL, Badesch DB, et al, “ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association,” <i>J Am Coll Cardiol</i>, 2009, 53(11):1573-619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/19389575/pubmed" id="19389575" target="_blank">19389575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24937180">
<a name="24937180"></a>Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/24937180/pubmed" id="24937180" target="_blank">24937180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16939634">
<a name="16939634"></a>Vatter H and Seifert V, “Ambrisentan, a Non-peptide Endothelin Receptor Antagonist,” <i>Cardiovasc Drug Rev</i>, 2006, 24(1):63-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ambrisentan-drug-information/abstract-text/16939634/pubmed" id="16939634" target="_blank">16939634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Volibris.1">
<a name="Volibris.1"></a>Volibris (ambrisentan) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8653 Version 233.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
